262 results
Page 3 of 14
8-K
EX-5.1
z0iyu1ge
12 May 22
Entry into a Material Definitive Agreement
8:31am
8-K
EX-1.1
b4kou4c 3l29j8ox4v1
12 May 22
Entry into a Material Definitive Agreement
8:31am
424B5
tg97x27k2 8uox
12 May 22
Prospectus supplement for primary offering
8:30am
S-8
EX-5.1
ggw 3nc73tcnwhf
18 Jan 22
Registration of securities for employees
5:12pm
8-K
EX-10.1
idf8n4o9f 6n
10 Jan 22
Departure of Directors or Certain Officers
4:28pm
8-K
EX-10.1
8v1wortrhnnab74gx
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-10.1
qei9 h8jly16mw
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-4.1
3duhm
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
14ihak
2 Sep 21
Seelos Therapeutics Announces Senior Management Appointments
4:01pm
8-K
EX-5.1
hxvlrg7x2bamb ld
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
wygnx 3xsw6bs
21 May 21
Prospectus supplement for primary offering
12:00am
8-K
EX-1.1
6ps7pawdgl247z8
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
8g2jslu7
19 May 21
Prospectus supplement for primary offering
4:08pm